Contineum Therapeutics Inc - Class A
Research Contineum Therapeutics Inc - Class A (CTNM) on Bullrun: market cap USD 641.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTNM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 641.31M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 15.15M
- Free cash flow-USD 11.51M
Valuation Snapshot
latest market cap is USD 641.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 59.98M | -USD 55.54M | n/a | -2.17 | USD 75.60M | USD 8.25M | USD 260.99M |
| FY2024 | USD 0 | -USD 42.26M | -USD 33.36M | n/a | -2.18 | USD 21.94M | USD 6.26M | USD 198.07M |
| FY2023 | USD 50.00M | USD 22.72M | USD 18.94M | n/a | 0.08 | USD 15.53M | USD 572.00K | -USD 67.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 641.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 426.57M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 378.77M | n/a | n/a | n/a |
About Contineum Therapeutics Inc - Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Contineum Therapeutics Inc - Class A's market cap?
Contineum Therapeutics Inc - Class A's market capitalization is USD 641.31M.
What does Contineum Therapeutics Inc - Class A do?
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.